Anaptysbio (ANAB) Revenue Growth (1y) (2017 - 2026)
Anaptysbio (ANAB) Revenue Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,200.25 Bn | 66,199.96 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 64.03% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 96.43% |
| 10 | Anaptysbio | 1.57 Bn | 1.28 Bn | - | -7.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.98% |
| Dec 31, 2025 | 200.00% |
| Sep 30, 2025 | 233.33% |
| Jun 30, 2025 | 102.93% |
| Mar 31, 2025 | 286.84% |
| Dec 31, 2024 | 177.62% |
| Sep 30, 2024 | 352.08% |
| Jun 30, 2024 | 217.08% |
| Mar 31, 2024 | 422.49% |
| Dec 31, 2023 | 80.10% |
| Sep 30, 2023 | 156.61% |
| Jun 30, 2023 | 184.54% |
| Mar 31, 2023 | 41.65% |
| Dec 31, 2022 | 394.56% |
| Sep 30, 2022 | -93.54% |
| Jun 30, 2022 | -93.92% |
| Mar 31, 2022 | -90.30% |
| Dec 31, 2021 | -98.32% |
| Mar 31, 2021 | 100.00% |
| Dec 31, 2020 | 1,900.00% |